Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway
Antonella Padella(University of Bologna), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Maria Chiara Fontana(Istituto Oncologico Romagnolo), Giovanni Marconi(University of Bologna), Gastone Castellani(University of Bologna), Elisabetta Petracci(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Torsten Haferlach(Martin Luther Christian University), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Nicoletta Testoni(Thrombolysis in Myocardial Infarction Study Group), Giovanni Martinelli(University of Bologna), Eugenio Fonzi(University of Bologna), Carmen Baldazzi(University of Bologna), Anna Ferrari(University of Bologna)
Cited by 7
Related Papers
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
|Journal of Clinical Oncology|2013|543